Medically reviewed by Jay N. Yepuri, MD Key Takeaways IBS-C is a disorder of gut–brain interaction, which means that the two-way communication between the gut and the brain is in disarray, leading to ...

Findings showed 30% of patients taking linaclotide 145mcg achieved the primary endpoint of combined responder. The Food and Drug Administration (FDA) has approved Linzess ® (linaclotide) for the ...

It can be uncomfortable to talk about IBS, but doing so can help you find support and feel less alone. Deciding who to tell and how much to share can help get the conversation started. Irritable bowel ...

For millions of Americans, bathroom trips bring anxiety rather than relief. Irritable bowel syndrome with constipation (IBS-C) impacts approximately one-third of all IBS cases, causing physical ...

Dear Dr. Roach: I'm a young adult male who has been diagnosed with irritable bowel syndrome with constipation (IBS-C). Until this diagnosis, I had never even heard of the condition. A colonoscopy and ...

A recent survey weighed the needs and experiences of IBS-C patients with the challenges healthcare providers face when treating them. Using an online questionnaire, the researchers surveyed patients ...

How Fiber Works in Your Body How Fiber Helps IBS-C What About FODMAPs? Fiber Supplements Best Fiber-Filled Foods Fiber is a must for regular bowel movements. But if you have irritable bowel syndrome ...

Please provide your email address to receive an email when new articles are posted on . Compared with placebo, LinZess significantly decreased abdominal symptoms such as bloating, discomfort and pain ...

How do you help patients with soft stool that won't move through manage idiopathic constipation? Join Drs Lin Chang and Anthony Lembo as they discuss nuanced decision-making around treating IBS ...

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a global GI-focused healthcare company, presented new data from four scientific abstracts during the American College of ...

Salix Pharmaceuticals has identified a blockage in the irritable bowel syndrome (IBS) care pathway. Based on an online survey of 724 people, the manufacturer of a pair of IBS treatments thinks more ...